Skip to main content

Table 1 Patient characteristics

From: Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients

Characteristic

Value

Age [years]

69 (45–89)

PSA [ng/dl]

70 (0.3–4742)

Time from initial diagnosis [years]

 ≤ 2

18 (27.3%)

 > 2 to ≤ 5

20 (30.3%)

 > 5

28 (42.4%)

Prior therapy

 Prostatectomy

29 (44%)

 Radiation

39 (59%)

 ADT

66 (100%)

 Enzalutamide

50 (76%)

 Abiraterone

47 (71%)

 Docetaxel

37 (56%)

 Cabazitaxel

24 (36%)

 Xofigo

7 (11%)

ECOG PS before first cycle

 0

18 (27%)

 1

41 (62%)

 2

5 (8%)

 3

2 (3%)

Site of metastasis

 Bone

60 (91%)

 Lymph node

49 (74%)

 Liver

29 (44%)

 Lung

10 (15%)

  1. Data are presented as n (%) or median (range)
  2. Abbreviations: PSA prostate-specific antigen, ECOG PS Eastern Cooperative Oncology Group Performance Status, ADT androgen deprivation therapy